Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4597)	10/20/2000 2:15:28 PM
From: Don Miller	Respond to of 10280

Bruce, I would contend that neither Nora nor Prozac II are failures, for now they have yielded to a more inviting economic prospect. Nora because J&J did not want to market in that sector any longer. Prozac II because both LLY and SEPR each think they have a better drugs with the same time line. I think SEPR could even license R-fluoxetine to a generic producer and let them finish the dosage redetailing tests. However SEPR currently thinks they do not want the competition in 2004.